New Study Indicates Martek's Omega-3 DHA Reduces Heart Disease Risk Factors

Data Show Increased Levels of 'Good' Cholesterol, Decreased Levels Of Triglycerides and a Beneficial Shift in 'Bad' Cholesterol

ORLANDO, Fla., Nov 10, 2003 -- Researchers presented results today at the American Heart Association's Scientific Sessions suggesting that 1,000 mg of DHA omega-3 fatty acid daily can favorably impact lipids and reduce cardiovascular disease risk factors in healthy adults. The study was designed to investigate the cardiovascular benefits associated with docosahexaenoic acid (DHA) and used Neuromins(R) DHA, manufactured by Martek Biosciences (Nasdaq: MATK), which comes from a natural vegetarian source and is free of contaminants that may be found in fish.

A researcher from the University of Maryland enrolled 96 healthy adults with normal cardiovascular profiles in the study, randomly placed into four treatment groups. Three groups took a daily dose of 200 mg, 600 mg or 1,000 mg of DHA (Neuromins(R)) and the fourth group took a placebo. Patients' lipid levels were measured at the outset of the trial and again at two and four weeks of supplementation. Patients receiving DHA experienced a five percent dose-dependent increase in HDL cholesterol (known as "good" cholesterol), with maximum effect occurring with 600 mg per day. Additionally, DHA supplementation resulted in a dose-dependent decrease in patients' triglyceride levels, with a maximum 13 percent reduction occurring with 1,000 mg per day. According to the American Heart Association, high levels of HDL cholesterol reduce a patient's risk of heart attack, while patients with high levels of triglycerides are at risk for developing cardiovascular disease.

According to the study, DHA supplementation also had a beneficial impact on patients' LDL cholesterol (known as "bad" cholesterol). While DHA supplementation at 600 and 1000 mg resulted in an overall five-to-eight percent increase in LDL cholesterol, this rise was largely attributed to a 28 percent increase in large, buoyant LDL particles, which pose little to no cardiovascular risk to patients. At the same time, there was no increase in small, medium or total LDL particles, which are associated with low levels of HDL cholesterol, high levels of triglycerides and increased risk of cardiovascular disease.

"This study suggests that one gram of DHA per day may lower triglycerides and raise HDL cholesterol by increasing the large protective HDL particles," stated lead investigator, Harry Oken, M.D., Clinical Associate Professor of Medicine at the University of Maryland. "This study corroborates other research indicating that DHA may promote cardiovascular health."

"The evidence continues to accumulate on DHA cardiovascular benefits," stated Henry "Pete" Linsert, Jr., Chairman and CEO of Martek. "Martek believes this study clearly indicates that DHA is the ultimate omega-3 fatty acid for patients seeking improved heart health."

Additional studies demonstrating the cardioprotective nature of Martek's Neuromins(R) DHA will be presented at AHA's Scientific Sessions on Wednesday, Nov. 12.

Neuromins(R) DHA contains the vegetarian, contaminant-free, Kosher, Halal omega-3 fatty acid manufactured under FDA inspected, GMP (Good Manufacturing Practice) conditions. The product is marketed nationwide as an adult nutritional supplement. For more information on DHA, visit

Martek Biosciences Corporation develops and sells products from microalgae. The Nutritional Products Group manufactures and sells two nutritional fatty acids, docosahexaenoic acid (DHA) and arachidonic acid (ARA). Martek has patented its DHA (DHASCO(R)) and ARA (ARASCO(R)) oil blend (Formulaid(R)) and sells it to infant formula manufacturers worldwide. Martek also sells its DHA oil, under the Neuromins(R) brand name, to the nutritional supplement industry, either directly or through a number of supplement manufacturers. The Fluorescent Products Group develops and sells a series of proprietary and non-proprietary fluorescent markers. These markers have been designed for use in a wide range of drug discovery and research applications.

This press release contains forward-looking statements regarding Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.